Combinatorial therapy of G47Δ with TSA has been evaluated in various types of tumors such as glioma and colorectal cancer [138], indicating that it led to the inhibition of vascular endothelial growth factor (VEGF) and the degradation of Cyclin D1. The gene discussed is VEGFA; the disease is central nervous system cancer.